selinexor sold brand name xpovio among others selective inhibitor nuclear export used anticancer medication works blocking action exportin thus blocking transport several proteins involved cancercell growth cell nucleus cytoplasm ultimately arrests cell cycle leads first drug mechanism common side effects include nausea feeling sick vomiting decreased appetite weight loss diarrhea tiredness thrombocytopenia low bloodplatelet counts anaemia low redblood cell counts low levels white blood cells hyponatraemia low blood sodium selinexor granted accelerated approval us food drug administration fda july use combination corticosteroid dexamethasone treatment adults relapsed refractory multiple myeloma rrmm received least four prior therapies whose disease resistant several forms treatment including least two proteasome inhibitors least two immunomodulatory agents monoclonal december selinexor approved fda combination bortezomib dexamethasone treatment adults multiple myeloma received least one prior clinical trials associated high incidence severe side effects including low platelet counts low blood sodium us food drug administration fda considers firstinclass selinexor approved medical use european union march selinexor approved combination bortezomib dexamethasone treatment adults multiple myeloma received least one prior selinexor also approved use combination steroid dexamethasone people relapsed refractory multiple myeloma received least four prior therapies whose disease refractory least two proteosome inhibitors least two immunomodulatory agents monoclonal antibody socalled quadrefractory pentarefractory treatment options first drug approved june us food drug administration fda approved additional indication selinexor treat adults relapsed refractory diffuse large bcell lymphoma dlbcl otherwise specified including dlbcl arising follicular lymphoma least two lines systemic european union selinexor indicated combination dexamethasone treatment multiple myeloma adults received least four prior therapies whose disease refractory least two proteasome inhibitors two immunomodulatory agents monoclonal antibody demonstrated disease progression last clinical study boston study used support fda approval patients multiple myeloma least one prior therapy onceweekly selinexor combination onceweekly bortezomib dexamethasonethe common adverse reactions cytopenias along gastrointestinal constitutional symptoms consistent previously reported selinexor studies adverse reactions manageable dose modifications andor standard supportive care common nonhematologic adverse reactions fatigue nausea decreased appetite diarrhea mostly grade events common grade adverse reactions thrombocytopenia lymphopenia fatigue anemia common adverse reactions incidence people diffuse large bcell lymphoma dlbcl excluding laboratory abnormalities fatigue nausea diarrhea appetite decrease weight decrease constipation vomiting grade laboratory abnormalities thrombocytopenia lymphopenia neutropenia anemia serious adverse reactions occurred people often thrombocytopenia leading cause dose gastrointestinal toxicity developed people grade hyponatremia developed central neurological adverse reactions occurred people including dizziness mental status prescribing information provides warnings precautions thrombocytopenia neutropenia gastrointestinal toxicity hyponatremia serious infection neurological toxicity embryofetal like selective inhibitors nuclear export sines selinexor works binding exportin also known karyopherin performs nuclear transport several proteins including tumor suppressors oncogenes proteins involved governing cell growth cell nucleus cytoplasm often overexpressed function misregulated several types inhibiting protein sines lead buildup tumor suppressors nucleus malignant cells reduce levels oncogene products drive cell proliferation ultimately leads cell cycle arrest death cancer cells vitro effect appeared spare normal nonmalignant inhibiting affects many different cells body may explain incidence adverse reactions thrombocytopenia example mechanistic dosedependent effect occurring selinexor causes buildup transcription factor nucleus hematopoietic stem cells preventing differentiation mature megakaryocytes plateletproducing cells thus slowing production new selinexor fully synthetic smallmolecule compound developed means structurebased drug design process known inducedfit docking binds cysteine residue nuclear export signal groove exportin although bond covalent slowly selinexor developed karyopharm therapeutics pharmaceutical company focused development drugs target nuclear transport approved united states july basis singlearm phase iib clinical trial fda decided grant accelerated approval despite previous recommendation fda advisory committee panel voted delay approving drug results ongoing phase iii study selinexor combination dexamethasone granted accelerated approval granted orphan drug fda granted approval xpovio karyopharm june us food drug administration fda approved additional indication selinexor treat adults relapsed refractory diffuse large bcell lymphoma dlbcl otherwise specified including dlbcl arising follicular lymphoma least two lines systemic approval based sadal multicenter singlearm openlabel trial participants dlbcl two five systemic participants received selinexor mg orally days one three december fda expanded selinexors approved indication include combination bortezomib dexamethasone treatment adults multiple myeloma received least one prior therapy january committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting conditional marketing authorization medicinal product nexpovio intended treatment relapsed refractory multiple applicant medicinal product karyopharm europe selinexor approved medical use european union march codename selinexor tested several preclinical animal models cancer including pancreatic cancer breast cancer nonsmallcell lung cancer lymphomas acute chronic humans early clinical trials phase conducted nonhodgkin lymphoma blast crisis wide range advanced refractory solid tumors including colon cancer head neck cancer melanoma ovarian cancer prostate compassionate use patients acute myeloid leukemia also pivotal clinical trial served support approval selinexor people relapsedrefractory multiple myeloma openlabel study patients known storm enrolled patients patients treated median seven prior treatment regimens including conventional chemotherapy targeted therapy bortezomib carfilzomib lenalidomide pomalidomide monoclonal antibody daratumumab nearly also undergone hematopoietic stem cell transplantation disease continued overall response rate including two stringent complete responses patients minimal response better median duration response months median progressionfree survival months median overall survival phase iii iii trials including use selinexor cancers combinations drugs used multiple november results multicenter phase iii randomized study evaluated participants relapsed refractory multiple myeloma received one three prior lines therapy published study designed compare efficacy safety certain healthrelated quality life parameters onceweekly selinexor combination onceweekly bortezomib plus lowdose dexamethasone svd versus twiceweekly plus lowdose dexamethasone vd primary endpoint study progressionfree survival pfs key secondary endpoints included overall response rate orr rate peripheral neuropathy others additionally boston study allowed patients vd control arm crossover svd arm following objective quantitative progression disease verified independent review committee irc boston study conducted clinical sites internationally although study one highest proportions patients highrisk cytogenetics compared velcadebased studies previously treated myeloma median pfs svd arm months compared months vd arm representing month increase median pfs hazard svd group also demonstrated significantly greater orr compared vd group vs patients received one prior line therapy also demonstrated higher orr svd arm compared vd arm vs importantly svd therapy compared vd therapy showed consistent pfs benefit higher orr across several important selinexor underwent clinical trial treatment phase randomized placebocontrolled singleblind trial named total participants severe treatment selinexor resulted higher mortality vs serious adverse events vs httpsenwikipediaorgwikiselinexor